ストックスクリーナーアプリを入手
2.22
0.45%
0.01
プレマーケット:
2.26
0.04
+1.80%
Grace Therapeutics Inc (GRCE) 最新ニュース
GRCE Q1 2026 Earnings: EPS Beats Estimates by Wide Margin Amid No Reported RevenueProfit Margin Analysis - newsline.com
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Should I Buy - Intellectia AI
GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Lelezard
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-07 | Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Sahm
Grace Therapeutics VP of Clinical Operations Departs Role - TipRanks
Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12‑month consulting agreement - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect | NDAQ:GRCE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics, Inc. (GRCE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - mykxlg.com
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Investors to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
GRCE Technical Analysis | Trend, Signals & Chart Patterns | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect - ACCESS Newswire
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect | NDAQ:GRCE | Press Release - Stockhouse
Grace Therapeutics (GRCE) Jumps 5.76%: Testing Resistance at $2.7 After Support HoldPullback Trade - newsline.com
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz - The National Law Review
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock RallyLong-Term Guidance - The Legal Advocate
GRCE Q1 2026 Earnings: EPS Surprises to the Upside Despite No RevenueFinal Results - The Legal Advocate
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineGuidance Accuracy Score - Newser
Grace Therapeutics Inc. (GRCE) Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Stock DipRevenue Guidance Update - The Legal Advocate
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - PR Newswire
Pomerantz LLP Investigates Claims for Grace Therapeutics Investors - Intellectia AI
Grace Therapeutics (GRCE) Gains +1.40% — Support Holds at $2.07 2026-05-20Intraday Profile - Newser
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - FinancialContent
Why Is Grace Therapeutics, Inc. (GRCE) Stock Down Today? - Meyka
Grace Therapeutics (GRCE) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.14Mature Phase - Newser
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
Grace Therapeutics (GRCE) Q1 2026 Earnings: $-0.14 EPS Surges Past $-0.29 EstimatesSocial Trade Signals - newser.com
ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics faces investigation after FDA rejects drug application, stock drops 45%. - Pluang
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - MSN
Grace Therapeutics (GRCE) Down -1.78% — How Low Could It Go? 2026-05-14Hedge Fund Inspired Picks - Newser
Number of shareholders of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Number of shareholders of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Largest borrow rate increases among liquid names - TipRanks
Grace Therapeutics, Inc. (GRCE) Eps Diluted (TTM) - Zacks Investment Research
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):